Disclosed positions

Estimated from their latest filings — positions may have changed since

$20.14M

combined est. value

Stock	Shares	Price	Value	Weight	As of
RLYBRallybio Corp	926,352	$15.96	$14.78M	73%	2026-05-19
NXTCNextCure, Inc.	722,419	$5.78	$4.18M	21%	2026-07-31
INMInMed Pharmaceuticals Inc.	800,000	$1.47	$1.18M	6%	2026-05-19

RLYB

Rallybio Corp

$14.78M

926,352 sh

NXTC

NextCure, Inc.

$4.18M

722,419 sh

INM

InMed Pharmaceuticals Inc.

$1.18M

800,000 sh

Activity

Open-market buy & sell volume

BuySell

Total +$2.66M bought · −$95.66M sold

Most bought

NXTC

$1.71M

INM

$721.5K

RLYB

$226.6K

All filings on record

Every Form 4 transaction we track for this filer

all 25buys 19sells 3

Stock	Transaction	Date	~6mo later
NXTCNextCure, Inc.	Buy $38.4K · 8,003 sh	2026-07-31	in progress
NXTCNextCure, Inc.	Buy $124.5K · 25,000 sh	2026-07-31	in progress
NXTCNextCure, Inc.	Buy $16.4K · 3,300 sh	2026-07-31	in progress
NXTCNextCure, Inc.	Buy $385.8K · 77,850 sh	2026-07-30	in progress
NXTCNextCure, Inc.	Buy $490.0K · 100,000 sh	2026-07-30	in progress
NXTCNextCure, Inc.	Buy $120.3K · 25,000 sh	2026-07-30	in progress
NXTCNextCure, Inc.	Buy $100.0K · 20,000 sh	2026-07-30	in progress
NXTCNextCure, Inc.	Buy $100.0K · 20,000 sh	2026-07-30	in progress
NXTCNextCure, Inc.	Buy $248.6K · 50,000 sh	2026-07-30	in progress
NXTCNextCure, Inc.	Buy $8.0K · 1,600 sh	2026-07-29	in progress
NXTCNextCure, Inc.	Buy $9.1K · 1,810 sh	2026-07-29	in progress
NXTCNextCure, Inc.	Buy $31.7K · 6,400 sh	2026-07-28	in progress
NXTCNextCure, Inc.	Buy $39.0K · 7,798 sh	2026-07-27	in progress
INMInMed Pharmaceuticals Inc.	Buy $299.8K · 200,000 sh	2026-05-19	in progress
INMInMed Pharmaceuticals Inc.	Buy $312.1K · 200,000 sh	2026-05-19	in progress
INMInMed Pharmaceuticals Inc.	Buy $109.7K · 68,551 sh	2026-05-19	in progress
RLYBRallybio Corp	Buy $2.8K · 200 sh	2026-05-19	in progress
RLYBRallybio Corp	Buy $139.8K · 10,000 sh	2026-05-19	in progress
RLYBRallybio Corp	Buy $84.0K · 6,009 sh	2026-05-18	in progress
KROSKeros Therapeutics, Inc.	Sell $13.19M · 743,358 sh	2025-10-15	—
KROSKeros Therapeutics, Inc.	Sell $4.52M · 254,669 sh	2025-10-15	—
KROSKeros Therapeutics, Inc.	Sell $77.94M · 4,391,237 sh	2025-10-15	—
KROSKeros Therapeutics, Inc.	Other $14.0K · 200 sh	2025-06-20	—
KROSKeros Therapeutics, Inc.	Other $98.0K · 1,400 sh	2025-06-20	—
KROSKeros Therapeutics, Inc.	Other $6.0K · 100 sh	2025-06-20	—

NXTCBuy

2026-07-31 · NextCure, Inc.

$38.4K

in progress

NXTCBuy

2026-07-31 · NextCure, Inc.

$124.5K

in progress

NXTCBuy

2026-07-31 · NextCure, Inc.

$16.4K

in progress

NXTCBuy

2026-07-30 · NextCure, Inc.

$385.8K

in progress

NXTCBuy

2026-07-30 · NextCure, Inc.

$490.0K

in progress

NXTCBuy

2026-07-30 · NextCure, Inc.

$120.3K

in progress

NXTCBuy

2026-07-30 · NextCure, Inc.

$100.0K

in progress

NXTCBuy

2026-07-30 · NextCure, Inc.

$100.0K

in progress

NXTCBuy

2026-07-30 · NextCure, Inc.

$248.6K

in progress

NXTCBuy

2026-07-29 · NextCure, Inc.

$8.0K

in progress

NXTCBuy

2026-07-29 · NextCure, Inc.

$9.1K

in progress

NXTCBuy

2026-07-28 · NextCure, Inc.

$31.7K

in progress

NXTCBuy

2026-07-27 · NextCure, Inc.

$39.0K

in progress

INMBuy

2026-05-19 · InMed Pharmaceuticals Inc.

$299.8K

in progress

INMBuy

2026-05-19 · InMed Pharmaceuticals Inc.

$312.1K

in progress

INMBuy

2026-05-19 · InMed Pharmaceuticals Inc.

$109.7K

in progress

RLYBBuy

2026-05-19 · Rallybio Corp

$2.8K

in progress

RLYBBuy

2026-05-19 · Rallybio Corp

$139.8K

in progress

RLYBBuy

2026-05-18 · Rallybio Corp

$84.0K

in progress

KROSSell

2025-10-15 · Keros Therapeutics, Inc.

$13.19M

—

KROSSell

2025-10-15 · Keros Therapeutics, Inc.

$4.52M

—

KROSSell

2025-10-15 · Keros Therapeutics, Inc.

$77.94M

—

KROSOther

2025-06-20 · Keros Therapeutics, Inc.

$14.0K

—

KROSOther

2025-06-20 · Keros Therapeutics, Inc.

$98.0K

—

KROSOther

2025-06-20 · Keros Therapeutics, Inc.

$6.0K

—

Outcomes measure each disclosed buy against the closing price ~6 months (120 trading days) later, with the S&P 500 over the same span for context. Pre-scheduled 10b5-1 plan trades are excluded from the record. Positions are estimated from the latest reported post-transaction holdings, split-adjusted, at the latest close. Built from SEC Form 4 filings and market prices — past outcomes, not predictions or advice.